Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia



Rating:

Share or cite this content

Citations should be made in the following way:
L. Richeldi (Rome, Italy), V. Cottin (Lyon, France), L. Islam (Welwyn Garden City, United Kingdom), G. Jenkins (Nottingham, United Kingdom), N. Kamath (Welwyn Garden City, United Kingdom), Y. Inoue (Osaka, Japan), N. Parmar (Welwyn Garden City, United Kingdom), J. Randhawa (Welwyn Garden City, United Kingdom), G. Raghu (Washington, United States of America). Challenges in setting up Phase III idiopathic pulmonary fibrosis studies during the COVID-19 pandemic: Experience from the STARSCAPE program. 462

Member's Comments

No comment yet.

Related content which might interest you: Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1800663; 10.1183/13993003.00663-2018 Year: 2019 PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients Source: International Congress 2016 – IPF clinical Year: 2016 A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials Source: Eur Respir J 2015; 46: 243-249 Year: 2015 Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry Source: Eur Respir J 2015; 46: 186-196 Year: 2015 Home oxygen saturation monitoring and quality of life in patients with idiopathic pulmonary fibrosis: A prospective multicenter trial Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014 Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences Source: Eur Respir Rev 2015; 24: 420-427 Year: 2015 Recombinant human pentraxin-2 for idiopathic pulmonary fibrosis: Design of STARSCAPE-OLE, a Phase III open label extension study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Effects of a 3-week pulmonary rehabilitation program in patients with idiopathic pulmonary fibrosis – A randomized, controlled trial Source: International Congress 2016 – Novel approaches for pulmonary rehabilitation in chronic lung diseases Year: 2016 Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: Randomised controlled trial Source: Annual Congress 2013 –The best posters in chronic care Year: 2013 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of IPF patients in a real-world clinical setting- An interim report Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward Source: Eur Respir J 2013; 42: 1446-1448 Year: 2013 Case study in cystic fibrosis: the US CF Foundation research and clinical development programmes Source: Research Seminar 2014 - Breaking down barriers to lung health: a better environment for better medicines Year: 2014 Validation of the recording of acute exacerbations of COPD in the clinical practice research datalink: Phase 1 results Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations Year: 2015 Predicting mortality in idiopathic pulmonary fibrosis. Which parameters should be used to determine eligibility for treatment? Analysis of a UK prospective cohort Source: International Congress 2016 – The best is yet to come in terms of lung function Year: 2016 Exploring barriers to Pirfenidone adherence in patients with idiopathic pulmonary fibrosis: a prospective study Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 Diagnosis of idiopathic pulmonary fibrosis: from guidelines to clinical practice Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009